393 results about "In vitro diagnostic" patented technology

The invention provides a multi-channel one-core multi-detection integrated detection method, which is applied to the technical field of in-vitro diagnosis and comprises the following steps: acquiring time sequence original signals of blood routine, liver function and kidney function channels; obtaining a baseline stable primary signal through cross-channel baseline trend coupling and adaptive correction; adopting a machine learning model to identify interference components and performing component offset to obtain a decoupling signal; mapping the decoupling signal into a physiological parameter value and carrying out rationality test; when the low credible parameter exists, a rechecking mechanism is triggered; performing weighted fusion on the basis of the rationality test result and the recheck signal to obtain a comprehensive parameter set; and finally generating a comprehensive detection report containing the credibility score. Cooperative processing and fusion analysis of multi-channel detection signals are realized, and the accuracy and reliability of a detection result are remarkably improved through interference identification and a dynamic recheck mechanism.

The application belongs to the technical field of immunology and in vitro diagnosis, and particularly relates to a rabbit-derived recombinant monoclonal antibody specifically recognizing type II grass carp reovirus VP4 protein, a eukaryotic expression method and application. The S6 gene in GCRV-II encodes VP4 protein, the application transfects the target gene S6 into HEK293 cells for expression and purification, cooperates with Freund's adjuvant to immunize New Zealand white rabbits, and uses ELISA, single B cell screening and eukaryotic expression technology to obtain a rabbit-derived recombinant monoclonal antibody specifically recognizing GCRV-II VP4 protein. The antibody has strong specificity, provides support for further establishment of specific type II grass carp reovirus diagnosis technology, and has great application value for development of GCRV-II related scientific research.

A method for automatically generating a research and development proposal for an in vitro diagnostic kit, performed by a server for automatically generating the research and development proposal, includes: acquiring an initial proposal including intended use information for the kit; providing the acquired initial proposal to a pre-trained language model; acquiring a specification (spec) for the kit from the language model receiving the initial proposal, wherein the acquired specification for the kit includes at least one of a technical specification to be used for the research and development of the kit, a resource specification for the research and development, a design specification for the kit, a regulatory approval specification that is needed to meet for approval, and a performance specification for the kit; and controlling to generate the research and development proposal for the kit including the acquired specification and the intended use information for the kit.

The invention relates to the technical field of in-vitro diagnostic kits, in particular to hollow porous monodisperse carboxyl polystyrene microspheres, a preparation method and application of the hollow porous monodisperse carboxyl polystyrene microspheres in a kit for quantitatively detecting MxA. The preparation method of the microspheres comprises the steps that firstly, hydrophilic polystyrene microspheres are prepared to serve as stable particles; then fully mixing the Pickering particles with a first oil phase to form Pickering stable particles; then a surfactant and a second oil phase are added, the mixed system is stirred at a high speed, and the second oil phase permeates into the surfaces or pores of Pickering stable particles through interface interaction and molecular diffusion; under the action of an initiator, the polymeric monomers are subjected to a polymerization reaction, the low-boiling-point organic solvent is evaporated out along with temperature rise, and a polymer with a core part of a hollow structure and a shell layer of a porous structure is formed; and adding a carboxyl-containing functional monomer to form a hydrophilic polymer chain on the surface of the polymer, thereby finally obtaining the hollow porous monodisperse carboxyl polystyrene microspheres.

The present invention relates to the field of allergens and more specifically to a novel isolated allergen from the species Cupressaceae shown to be a primary sensitizer for severe peach allergy mediated by the protein Pru p7. The allergen is homologous with Pru P7 in peach, a protein belonging to the Gibberelin Regulating Proteins (GRPs). The novel allergen also 5 shares high sequence homology among other species from the Cupressaceae family and there is therefore also provided additional novel allergens in two other species of the Cupressaceae family. The novel allergens find use in the in vitro diagnosis of, treatment and / or prevention of Type 1 Cupressaceace pollen allergy and Cupressaceace pollen-associated food allergies.

The invention discloses a monoclonal antibody which is specifically combined with a microtubule associated protein tau (microtubule associated protein with 217 Thrphorylation, pTau217) of which the 217 site is phosphorylated by threonine, and a preparation method of the monoclonal antibody. The invention provides an amino acid sequence of a variable domain of the monoclonal antibody, and an amino acid sequence of a complementary determining region (CDR) contained in the amino acid sequence of the variable domain of the monoclonal antibody. The monoclonal antibody disclosed by the invention has the capability of specifically recognizing and remarkably combining pTau217, and can be used for developing and producing pTau217 clinical in vitro diagnosis (IVD) medical equipment products based on an immunological detection principle as a reagent raw material.

This invention discloses a combination of biomarkers for the auxiliary diagnosis of chronic pain comorbid with depression and its application, belonging to the fields of in vitro diagnostics (IVD) and clinical testing technology. The biomarker combination includes interleukin-6 (IL-6), interleukin-12 (IL-12), and the concentration ratio of kynurenic acid to 3-hydroxykynurenine (KYNA / 3-HK). This invention also discloses the application of this biomarker combination in an in vitro diagnostic kit for chronic pain comorbid with depression. Experimental results show that the diagnostic efficacy of this biomarker combination (AUC=0.871) is significantly better than that of a single biomarker, effectively distinguishing patients with chronic pain comorbid with depression from those without chronic pain, providing an objective auxiliary diagnostic tool for clinical practice.

A personalized medical method for treating amyotrophic lateral sclerosis (ALS), comprising screening out a subpopulation of ALS patients having highly immunologically active causes, and administering a therapeutically effective amount of a Janus kinase (JAK) inhibitor to the patients screened out thereby. Also provided are the use of a corresponding JAK inhibitor, an in vitro diagnostic method for screening patients, a kit, and a computer-implemented method. After patients screened out by means of the method are treated with a JAK inhibitor (such as tofacitinib), the level of a nerve damage marker is significantly reduced, and clinical functions are stabilized or improved, and therefore the present invention shows a good therapeutic prospect.

An automated method of washing a fluidic system 210 of an IVD analyzer 200 from a previous fluid is disclosed, the fluidic system 210 comprising at least one fluidic path 211, 213, 215. The method comprises controlling by a controller 250 a pump 240 and at least one fluid-selection valve 230 for pumping a wash fluid 221 and / or air 232 through the at least one fluidic path, wherein in a time-priority mode 10 the method comprises pumping at higher speed air, in a first step 11, in order to remove the previous fluid from the at least one fluidic path, and wash-fluid plugs alternated to air plugs, in a second step 12, in order to wash out residuals of the previous fluid, and wherein in a wash-fluid-priority mode 20 the controller 250 is configured to operate according to either a sample-wash mode 30 if the previous fluid is a sample 2 or according to an other-fluid-wash mode 40 if the previous fluid is any fluid other than a sample 2, wherein in the sample-wash mode 30 the method comprises pumping air at lower speed, in a first step 31, in order to remove the previous fluid from the at least one fluidic path, pumping at least one wash-fluid plug at higher speed, in a second step 32, and pumping wash-fluid plugs alternated to air plugs at lower speed, in a third step 33, in order to wash out residuals of the previous fluid, and wherein in the other-fluid-wash mode 40 the method comprises pumping air at lower speed, in a first step 41, in order to remove the previous fluid from the at least one fluidic path and pumping wash-fluid plugs alternated to air plugs at lower speed, in a second step 42, in order to wash out residuals of the previous fluid.

1. The name of the design product: pathological scanner. 2. The use of the design product: the design product is used for in-vitro diagnosis and scientific research. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: design 1 perspective view 1. 5. Design 1 is designated as the basic design.

Provided are a test reagent that reduces non-specific adsorption and is capable of detecting a low-concentration target substance, and a detection method including using the test reagent. The test reagent is a test reagent for in vitro diagnosis, and comprises: a thiourea compound; and resin particles, wherein the resin particles each have a sulfur element.

The invention relates to the field of in-vitro diagnostic reagents, in particular to application of a reagent for detecting TREM2 in preparation of a diagnostic kit for chronic kidney disease osteoporosis. The invention finds that the TREM2 signal channel is closely related to the common pathological background of chronic kidney disease and osteoporosis. Therefore, the TREM2 can be used as an expression characteristic and a molecular diagnosis marker in the chronic kidney disease-related osteoporosis, so that the chronic kidney disease-related osteoporosis can be subjected to early diagnosis. On the basis, the invention provides application of the TREM2 detection reagent in preparation of the chronic kidney disease osteoporosis diagnosis kit, and the application prospect is good.

The amount of certain metabolomic markers from the lipid metabolism can be used for the highly specific and sensitive in-vitro diagnosis of ADHD.

The invention belongs to the field of in-vitro diagnostic reagents, and particularly relates to application of a reagent for detecting biomarkers in serum in preparation of a cerebral arterial thrombosis diagnostic kit. The invention determines that the concentrations of lactic acid, isoleucine, fumaric acid, ketoglutaric acid, hypoxanthine, tyrosine, histidine and inosine in serum of a cerebral arterial thrombosis (IS) patient are significantly related to major atherosclerosis (LAA) and minor artery occlusion (SAO), so that the concentrations of the biomarkers can be used as a basis for diagnosing IS and distinguishing LAA and SAO.

The invention belongs to the technical field of in-vitro diagnosis and anesthesia monitoring. The invention discloses a serum protein marker combination for evaluating anesthesia depth and application of the serum protein marker combination. The composition is composed of orexin, S100 calcium binding protein B, C reactive protein and gamma-aminobutyric acid A type receptor alpha1 subunit, and can synergistically reflect the anesthesia sedation state from multiple dimensions. The invention also provides a detection kit containing the marker and application of the detection kit in evaluation of anesthesia depth. The combination has the advantages of being high in accuracy, objective, stable and easy to detect, can serve as an effective supplementary tool of an existing nerve electrophysiology monitoring technology, and provides a new reference means for intraoperative sedation depth monitoring and precise anesthesia management.

The invention relates to a reagent disc control method and device, a computer readable storage medium, computer equipment and a system, and belongs to the field of in vitro diagnos.The method comprises the steps that a to-be-controlled reagent disc is displayed in a reagent disc management interface, reagent rings in the to-be-controlled reagent disc correspond to entity reagent rings in a target entity reagent disc in a one-to-one mode, and the entity reagent rings in the target entity reagent disc correspond to the reagent rings in the target entity reagent disc in a one-to-one mode; reagent ring operation controls in one-to-one correspondence with the reagent rings are further displayed in the interface, in response to unlocking triggering operation on the reagent ring operation controls, the reagent rings corresponding to the reagent ring operation controls corresponding to the operation are switched to be in an unlocking state, and the entity reagent rings corresponding to the reagent rings are controlled to be switched to be in an experiment stopping state. The entity reagent rings corresponding to the reagent rings still in the locking state maintain the experiment state. Therefore, different entity reagent rings can be respectively controlled through different reagent ring operation controls, independent control of each entity reagent ring is realized, mutual influence is avoided, and the experiment efficiency is effectively improved.

This utility model relates to the field of in vitro diagnostic automation equipment technology, and discloses a feeding slide structure and a testing analyzer, including: a hopper having an inlet end and an outlet end. A slide is set at the outlet end and partially extends into the hopper. A receiving component is set at the part of the slide extending into the hopper, and is located at the landing point of the reaction cup after entering the hopper. The cup-guiding structure includes a guiding plate located above the slide, one end of which is rotatably set close to the outlet end, and the other end extends towards the slide. The guiding plate is used to correct the posture of the reaction cup entering the slide. The feeding slide structure provided by this utility model improves the correction efficiency of the reaction cup through the receiving component, reduces the time the reaction cup takes to pass through the hopper, can adapt to the feeding requirements of high-speed equipment, reduces the probability of cup stacking and jamming, and can also prevent malfunctions caused by cup overflow through the guiding plate.

The application provides a recombinant cholesteryl esterase, a polynucleotide thereof, a recombinant plasmid, an expression system and application. The application belongs to the technical field of protein engineering, and specifically, the amino acid sequence of the recombinant cholesteryl esterase provided by the application is shown as SEQ ID No. 1, and the nucleotide sequence for encoding the recombinant cholesteryl esterase is shown as SEQ ID No. 2. The sequence of the recombinant cholesteryl esterase provided by the application has a full length of 482 amino acids, is derived from Aspergillus ruber, has the advantage of high thermal stability, and has a thermal stability deviation of less than 10% after thermal storage at 37 DEG C for 11 days and after 30 days of on-board opening, and has a wide application prospect in the field of in-vitro diagnostic reagents.

A cradle assembly according to one embodiment of the present invention may include a first cradle supported on a bottom surface and having an in-vitro diagnostic device coupled to its front surface, and a second cradle coupled to cover a portion of an upper surface of the first cradle and selectively coupled to correspond to a front end or a rear end of the upper surface of the first cradle, having the in-vitro diagnostic device coupled to its front surface.

The invention provides an ELISA (Enzyme-Linked Immunosorbent Assay) detection kit for detecting rabbit hemorrhagic disease virus infection, and belongs to an in-vitro diagnostic reagent. The invention discloses application of RdRp protein in preparation of a detection kit for detecting rabbit hemorrhagic disease virus infection or distinguishing rabbit hemorrhagic disease virus infection and vaccine immunity. The RdRp protein has good conservative property in RHDV strains of GI.1 and GI.2 types at the same time, and the anti-RdRp protein antibody only exists in a rabbit hemorrhagic disease virus infected body and is not generated in a vaccine immunized body, so that the RdRp protein can be used for distinguishing rabbit hemorrhagic disease virus infection and vaccine immunization based on the specific binding property of the RdRp protein and the anti-RdRp protein antibody; the method greatly simplifies the diagnosis and identification operation, and has the advantages of good accuracy and repeatability, high detection sensitivity, strong detection specificity and great popularization and application value.

The present invention relates to peptide conjugates that comprise a plant-derived oligopeptide capable of crossing the blood-brain barrier (BBB) and a therapeutic or diagnostic agent. The BBB-penetrating oligopeptide is an oligopeptide according to Formula I, Asp–R2–Gly–Leu–R5–R6–R7–Leu–Gly–R10–R11–R12, wherein R2 represents Arg, Lys, Cyt, D-Arg or Orn; R5 represents Phe, Arg, Lys, His, Trp, Tyr, D-Tyr, D-Phe, Orn, 4-aminophenylalanine or 3-phenylpropionate; R6 represents Pro, Leu, Glu or Lys; R7 represents Phe or Trp; R10, R11 and R12 each independently represent Lys, Arg or Orn; or an oligopeptide according to Formula II, Glu–R2'–R3'–Gly–R5'–R6'–Glu–R8'–R9'–R10'–Glu–R12'–Leu–Pro–Gly, wherein R2', R3', R8', R10' and R12' each independently represent Lys, Arg or Orn; R5' represents Phe, Ile, Arg, Lys, His, Trp, Tyr, D-Tyr, D-Phe, 4-aminophenylalanine, or 3-phenylpropionate; R6' represents Met, Leu, Ile, Asn, norleucin, D-norleucin, seleno- methionine or D / L-2-hydroxy-(4-methylseleno)butanoic acid; and R9' represents Leu or Ile. The conjugates comprising a BBB-penetrating oligopeptide compound and a therapeutic agent can be used in treatments for diseases of the central nervous system (CNS). Furthermore, conjugates with a BBB-penetrating oligopeptide compound and a diagnostic agent can be used in both in vivo and in vitro diagnostic methods.

The application provides a control method and device of an in-vitro diagnostic equipment and electronic equipment, the method is applied to a controller of the in-vitro diagnostic equipment, the in-vitro diagnostic equipment comprises a controller, multiple turntables and multiple mechanical hands; the control method of the in-vitro diagnostic equipment comprises the following steps: determining an idle duration and a first action duration; controlling the mechanical hand to perform a preset action within the idle duration; judging whether the mechanical hand completes the preset action within the idle duration; if the mechanical hand completes the preset action within the idle duration, controlling each turntable to perform a corresponding action within the first action duration; by setting the idle duration and the first action duration, the mechanical hand is controlled to perform an action within the idle duration, and each turntable is controlled to perform a corresponding action within the first action duration, the consistency of equipment actions is improved, the consistency of processing time of each group of samples is improved, the stability and consistency of sample processing are ensured, the efficiency is improved, and the user experience is improved.

The present invention relates to a method and a kit for the in vitro diagnosis of infection by enterobacteria with a hypervirulent genotype, such as the enterobacterium Klebsiella pneumoniae (Kpn) with a hypervirulent genotype, by means of real-time PCR, end-point PCR, or real-time probe-based PCR.

The application is suitable for the field of in-vitro diagnosis equipment, and discloses a liquid chromatograph. The liquid chromatograph comprises a liquid phase fluid conveying assembly, a chromatographic column, a detector and a controller; the liquid phase fluid conveying assembly comprises a storage component, a first driving component and a second driving component independent of the first driving component, the first driving component is used for driving a first liquid phase fluid from a first container to the storage component and driving a second liquid phase fluid from a second container to the storage component, so that the first liquid phase fluid and the second liquid phase fluid are mixed in the storage component at a preset ratio to form a third liquid phase fluid of a single concentration and are stored in the storage component; and the second driving component is used for driving the third liquid phase fluid to flow through the chromatographic column from the storage component, so that the third liquid phase fluid elutes a test liquid adsorbed on the chromatographic column. The application can realize the function of isocratic elution by using the liquid phase fluid prepared on line from two liquid phase fluids.

The invention discloses an acyl-coenzyme A oxidase mutant as well as an expression strain and application thereof. On the basis of acyl coenzyme A oxidase derived from marine microorganisms, mutation sites are designed through Saprot and scored, and mutation is introduced through overlapping extension PCR (polymerase chain reaction), so that a mutant gene is obtained. After the engineering bacteria containing the mutant plasmids are subjected to induced expression, the acyl-coenzyme A oxidase with improved stability and specific enzyme activity is obtained. Under the condition of 37 DEG C, the stability of the mutant is improved by 1.3 times. When palmitoyl coenzyme A is used as a substrate, the specific enzyme activity of the mutant is improved to 1.5 times. The mutant has application value in an in-vitro diagnostic kit for detecting free fatty acid by an enzyme method.

The invention relates to the field of in-vitro diagnosis, and discloses a peripheral red blood cell image segmentation method based on self-adaption and edge enhancement, and the method comprises the steps: obtaining a to-be-segmented red blood cell image; performing contour enhancement on the to-be-segmented red blood cell image to obtain a target red blood cell image; calculating a gray level histogram of the target red blood cell image, and extracting an envelope line in the gray level histogram; determining two main wave crests on the envelope line and a wave trough between the two main wave crests through a maximum value filtering method; performing threshold segmentation on the target red blood cell image by taking the pixel value corresponding to the trough as a threshold to obtain a binary image; carrying out segmentation point detection and matching on the binary image, and connecting the matched segmentation points to segment independent red blood cells; and performing ellipse fitting on the independent red blood cells to optimize the contour of the red blood cells. According to the method disclosed by the invention, the problem of effectively segmenting the red blood cells is solved, so that the adhered red blood cells and low-pigment red blood cells are effectively segmented out.

A cartridge is described. The cartridge may include a substrate having a plurality of wells arranged along a flow path, a first subgroup of dried Mastermix reagents contained within a first well of the plurality of wells, a second subgroup of dried Mastermix reagents contained within a second well of the plurality of wells, and a third subgroup of dried Mastermix reagents contained within a third well of the plurality of wells. Collectively, the Mastermix reagents in the first subgroup, the second subgroup, and the third subgroup may include all reagents needed for performing nucleic acid amplification.

The invention discloses an mRNA (messenger Ribonucleic Acid) quality control product of human papilloma virus as well as a preparation method and application thereof, and belongs to the technical field of in-vitro diagnosis quality control. The method comprises the following steps: chemically synthesizing an HPV E6 / E7 gene DNA sequence, respectively cloning the HPV E6 / E7 gene DNA sequence into a cloning vector to construct a synthetic plasmid template, further preparing a nucleic acid fragment containing E6 / E7 mRNA through in-vitro transcription, carrying out absolute quantification through a digital PCR technology, mixing the nucleic acid fragment with human cervical cancer cell line RNA without any HPV sequence, and screening to obtain the HPV E6 / E7 gene DNA sequence. And the mRNA quality control product with stable structure and accurate value is prepared through a vacuum freeze drying technology. The quality control product can simulate HPV E6 / E7 mRNA in a clinical sample, has comprehensive types, is suitable for accurate evaluation of sensitivity, specificity, precision and other analysis performances of an HPV E6 / E7 mRNA detection kit, provides a key quality control tool for accurate risk stratification of cervical cancer, and is suitable for various detection platforms.

This invention relates to the field of in vitro diagnostic technology, and more particularly to a method for determining cortisol levels and its application. This invention provides a pretreatment reagent combination for liquid chromatography, a method for pretreating urine samples in liquid chromatography, and a method for detecting cortisol levels in urine. The method for detecting cortisol levels in urine samples provided by this invention offers convenient and rapid pretreatment, and through method validation, demonstrates excellent performance indicators.

The utility model discloses a screw cap type deformable filtering device for preventing empty suction and blockage of a reagent needle, which comprises a screw cap, a hollow part is arranged in the middle of the screw cap, a latex connecting piece is arranged in the hollow part, a polytetrafluoroethylene film is arranged in the middle of the latex connecting piece, and a core accessory of the filtering device is a needle-shaped polytetrafluoroethylene film. Due to the excellent chemical characteristics, the filter material is suitable for reagents with various chemical properties, and the filter material can stably play a role in filtering acidic, alkaline and organic reagents. Under extreme environments such as high temperature and low temperature, normal work can be ensured, and the filtering effect cannot be influenced by environmental factors. The precise aperture design can effectively intercept tiny bubbles and particles which may cause empty suction and blockage of the reagent needle, so that the purity of a reagent extracted by the reagent needle is extremely high, an accurate and reliable reagent is provided for in-vitro diagnosis and detection, and the accuracy of a detection result is ensured.